Baird Upgrades Celgene (CELG) to Outperform
More News related to CELG
- XplosiveStocks.com:DLTR, INFY, ENDP, CTSH, CELG, PLCM Hot Stocks on the Move
- BridgewaterEquity.com Free Fundamental Sector & Market Research on SOHU, JBLU, PLCM and CELG
- Ameriprise Financial Names Celgene (CELG) a Top Pick for 2009
- Baird Downgrades Celgene (CELG) to Neutral
- European Commission Grants VIDAZA(R) Full Marketing Authorization for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukaemia (AML)
More News related to Upgrades
- Buckingham Research Maintains a 'Neutral' Rating on Wal-Mart (WMT), See Upside/Downside Fairly Balanced
- Wedbush Morgan Maintains a 'Hold' on Majesco Holdings (COOL), Impressed With Progress But Investors Remain Skeptical
- Wedbush Morgan Maintains a 'Hold' on Family Dollar Stores (FDO), Raises Price Target and Estimates
- Wedbush Morgan Maintains a 'Buy' on ON Semiconductor (ONNN), Raises Price Target
- Analyst Round-Up: Intuitive Surgical (ISRG) - 3 Downgrades, 2 Price Target Cuts
Baird upgrades Celgene (Nasdaq: CELG) from Neutral to Outperform. Price target $66.
Celgene Corporation is an integrated biopharmaceutical company.
Related Categories
UpgradesStocks Mentioned
-0.39Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
